The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLong Ideas - Sucampo Pharmaceuticals (NASDAQ:SCMP) announced Wednesday that its lead drug, Amitiza, received approval for marketing in the U.K. for chronic idiopathic constipation (CIC). This marks the … Continue Reading
Read nowLong Ideas - Amarin Corp. (NASDAQ:AMRN) is under pressure for a second day on investor concerns related to the FDA pushing back a decision on NCE status for … Continue Reading
Read nowQuick Picks - After the markets’ close Tuesday, Santarus Inc. (NASDAQ:SNTS) reported top-line data from a phase III trial of rifamycin SV MMX, sending shares up 6% in … Continue Reading
Read nowQuick Picks - On Wednesday morning, Opexa Therapeutics (NASDAQ:OPXA) announced the initiation of a Phase IIb trial, called Alibi-T, for Tcelna, the company’s T-cell therapy for multiple sclerosis. … Continue Reading
Read now- Last week, PropThink reported on Elan’s (NYSE:ELN) potential to fall as a result of bapineuzumab failures and disappearing buy-out speculation. We cited an article from … Continue Reading
Read nowQuick Picks - After a run-up to $1.44 last week, Chelsea Therapeutics (NASDAQ:CHTP) has been giving up gains as momentum ebbed and the company released no major updates … Continue Reading
Read nowLong Ideas - The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will meet this Thursday to discuss the NDA for Cornerstone Therapeutics’ (NASDAQ:CRTX) lixivaptan for the treatment … Continue Reading
Read now
